Non-Small Cell Lung Cancer and Molecular Subtypes
The portfolio is centered on non-small cell lung cancer across advanced, metastatic, and resected settings, with particular attention to molecularly defined disease.
- ALK-positive and ROS1-positive lung cancer
- MET exon 14 mutated disease
- BRAF V600E-mutant lung cancer
- Advanced non-squamous NSCLC
Research also includes post-treatment disease control and adjuvant strategies for patients with resected early-stage disease.
Immunotherapy and Immune-Based Combinations
Several studies focus on immune checkpoint inhibitors and related combinations in thoracic malignancies, including maintenance, first-line, and post-induction settings.
- PD-1 and PD-L1 blockade
- Dual immunotherapy combinations
- Anti-VEGF and immunotherapy pairings
- Maintenance treatment after induction therapy
This area also covers use in older patients and in individuals with limited functional reserve.
Thoracic Malignancies Beyond NSCLC
The sponsor funds research in other thoracic cancers and related rare malignancies, extending its scope beyond common lung cancer subtypes.
- Pleural mesothelioma
- Small cell lung cancer
- Poorly differentiated neuroendocrine carcinomas
- Extensive-stage SCLC
These studies address recurrent, relapsed, and pre-treated disease populations with limited therapeutic options.
Perioperative and Adjuvant Therapy
Research includes treatment strategies around surgery, with emphasis on adjuvant therapy, perioperative risk reduction, and disease-free survival in resected lung cancer.
- Completely resected stage I, II, and IIIA disease
- Postoperative chemotherapy
- Adjuvant immunotherapy
- Prognostic assay-guided treatment selection
These trials also include patients with high-risk features after complete resection of non-squamous tumors.
Complex Clinical Situations and Comorbid Lung Disease
The sponsored trials also address thoracic cancer care in patients with challenging clinical profiles, including poor performance status and coexisting lung disease.
- Interstitial lung disease
- Poor general status
- Unresectable stage III disease
- Older or medically unfit patients
These studies examine treatment tolerance and disease management in populations often underrepresented in oncology research.
